ProQR Therapeutics develops RNA editing medicines for liver and nervous system diseases using its Axiomer platform. PRQR reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for PRQR are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in PRQR in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRQR is in one of them and how their past PRQR trades turned out.
ProQR is a biotechnology company based in Leiden, Netherlands, that develops RNA editing medicines. It uses its proprietary Axiomer platform, which directs enzymes already present in cells to make precise changes in RNA, to build treatments for diseases of the liver and central nervous system. Its lead candidate is in a Phase 1 trial in healthy volunteers, and its pipeline also covers Rett syndrome, MASH, a liver disease, and cardiovascular disease. The company also works with Eli Lilly on drug targets under a licensing and research collaboration.
